Navigation Links
InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Date:7/24/2008

BRISBANE, Calif., July 24 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release second quarter 2008 financial results and provide a business update on Thursday, July 31, 2008 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 57393097. To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 57393097.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune to Present at Jefferies Healthcare Conference
2. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
3. InterMune to Present at Citigroup Healthcare Conference
4. InterMune to Present at Bank of America Health Care Conference
5. InterMune to Present at Deutsche Bank Health Care Conference
6. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
7. Evotec Expands Collaboration With InterMune
8. InterMune to Present at the SIGnificant Options in Healthcare Conference
9. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
10. InterMune Announces Closing of Public Offering of Common Stock
11. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2020)... ... 03, 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company ... Known as MediVet Biologics since its formation in 2016, the company is relaunching ... Health will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... ... July 29, 2020 , ... Editas Medicine, ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell ... into a strategic partnership whereby Catalent will provide support for the development, manufacturing, ...
(Date:7/18/2020)... ... 2020 , ... After research model surgery and catheter implantation, the long journey ... the beginning of a successful study, while protecting and accessing the catheter or device ... of Surgery from Envigo in a live webinar on Wednesday, ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... Technology (MIT) has expanded the company’s exclusive license to include clinical applications ... point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast ...
Breaking Biology Technology:
(Date:8/21/2020)... ... 2020 , ... NDA Partners Chairman Carl Peck, MD ... expertise in clinical trial planning and feasibility, regulatory inspection readiness, and clinical investigator ... career, Mr. Movahhed has helped design and manage oncology, neurology, cardiovascular, and anti-infective ...
(Date:8/5/2020)... ... 05, 2020 , ... Regenative Labs has received approval from the Centers for ... them the first Wharton’s jelly allografts to be assigned a Q code and be ... the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P by ...
(Date:7/18/2020)... , ... July 16, 2020 , ... ... demonstrates the effectiveness of the Invictus Medical Neoasis™ active noise control device to ... study reported that the Neoasis™ device attenuated the alarm sounds from patient monitors, ...
Breaking Biology News(10 mins):